Celerion https://validator.w3.org/feed/docs/rss2.html Sites Home ClinQuick®: Rapid Clinical Trial Execution Our Global Locations Clinical Protocol Development Biomarker Analysis Services Data Management & Biometric Services Global Clinical Development Solutions Clinical Data Science Services Celerion Achieves Milestone With CLIA Certification for Its Bioanalytical Laboratory, Expanding Capabilities in Clinical Trials and Diagnostic Testing Entering the NASH Race: Tips for Early Clinical Development Zurich, Switzerland Open for Business: Early Phase Clinical Drug Development during the COVID-19 Pandemic Tobacco Assays Belfast, UK Phoenix, Arizona 12 Questions to Help Guide Renal Impairment PK Study Design Bioanalytical Assays Celerion Receives a 2023 CRO Leadership Award in All Categories for the Eighth Year Running Celebrating a Decade of Biosimilars Development Adaptive Trial Designs Lincoln, Nebraska How Healthy Volunteer Studies can Accelerate Oncology Drug Development Celerion Honored With Prestigious CRO Leadership Award for Ninth Consecutive Year  PBMCs or Whole Blood? Strategic Applications in Phase I Studies Tackling the Complexity of Complex Generic Drug Development Celerion Recognized as 2020 CRO Leadership Champion for Reliability and Receives CRO Leadership Award for Capabilities, Compatibility, Expertise, and Quality Expertise Lincoln, Nebraska Celerion Expands Zurich Bioanalytical Laboratory to Meet Growing Market Demand Leadership Team Jo Goodman Joins Celerion as Vice President of Bioanalytical Services Celerion Receives CRO Leadership Award for 6th Consecutive Year COVID-19 Vaccines in Development Immunogenicity Testing Services Regulatory Medical Writing & Reporting Biosimilar Testing Services Drug Development & Regulatory Affairs Services Modeling and Simulation Services Monitoring & Project Management Services Key Clinical Pharmacology Studies to Support Biologic Drug Regulatory Submission Bioavailability/Bioequivalence-TEST GLP-1 Agonist-Induced Delayed Gastric Emptying – A Clinical Pharmacology Perspective Pharmabiotics – Spreading Culture to Therapeutic Drugs Celerion’s US Pharmacies Expand On-Site Services, Ensure cGMP FDA Compliance for Phase 1 Investigational Drugs COVID-19, Kawasaki and the Cytokine Storm The Platforms and Promise of COVID-19 Vaccines Reframing the Definition of Obesity Celerion Expands UK Phase 1 Clinical Research Operations With New Agreement to Relocate to Queen’s University Belfast’s iREACH Health – Clinical Research Innovation Center